Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

eduction in body weight of healthy obese people who completed 48 weeks of treatment in the absence of diet and exercise. Moreover, early response tended to predict longer term weight loss among the majority of study completers. Patients on Empatic also demonstrated a significant improvement in quality of life scores relative to those treated with placebo.

Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)

The Orexigen management team will host a teleconference and webcast to discuss the third quarter 2008 financial results and recent business highlights. The live call may be accessed by phone by calling (800) 860-2442 (domestic) or (412) 858-4600 (international). The webcast can be accessed live on the investor relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... Best Sanitizers, Inc., the first company to ... asks food processors and food handling professionals to prepare ... currently using to Best Sanitizers’ Alpet® E3 Plus ... fighting cross-contamination and the spread of pathogens in the ... key criteria that make a hand sanitizer most effective, ...
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
... Spine announced today that it received a revised FDA ... interbody implant with integrated fixation and an anterior screw ... stand-alone interbody devices with integrated fixation.   The new code ... code for cervical interbody devices is OVE.   In addition ...
... Henrik Quintel is a graduate computer scientist with a ... on a model that improves the understanding of brain disorders. ... software AMUSE from Viennese software producer LieberLieber. In ... fan of Vienna: "I actually came upon the idea for ...
... has announced the formation of a Medical Advisory Council ... (MiCK) assay for apoptosis , a new assay designed ... patients. DiaTech has introduced this technology for individual patient ... companies in validating new drugs that may be more ...
Cached Biology Technology:FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation 2Visionary With a Caterpillar 2DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3
(Date:8/28/2014)... America (ESA) is pleased to announce the selection of ... Society. Honorary Membership acknowledges those who have served ESA ... the affairs of the Society that has reached an ... the ESA Governing Board and then voted on by ... the Awards Ceremony at Entomology 2014, ESA,s Annual Meeting ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
(Date:8/28/2014)... have identified the developmental on-off switch for Streptomyces ... than two-thirds of the world,s naturally derived antibiotic medicines. ... whether it is possible to manipulate this switch to ... study, appearing August 28 in Cell , found ... cyclic-di-GMP and a larger protein called BldD ultimately controls ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... BOSTON AND NEW YORK The Damon Runyon ... Medical Center researcher John Rinn, PhD, has been awarded ... prize is made to early-career researchers who are using ... also a member of the faculty at the Broad ...
... a precise biosensor for detecting blood glucose and ... structures called single-wall carbon nanotubes anchored to gold-coated ... tetherball. Each tetherball is a sensor and is ... acts as both a tether and ultrathin wire ...
... Reporting in the journal Nature , researchers ... Molecular Biology in the Kimmel Cancer Center at Jefferson, ... The protein, AIM2 (absent in melanoma 2), is involved ... that is produced by infection with viral or microbial ...
Cached Biology News:BIDMC scientist John Rinn, Ph.D., receives Damon-Runyon Rachleff Innovation Award 2Nano-tetherball biosensor precisely detects glucose 2Nano-tetherball biosensor precisely detects glucose 3Nano-tetherball biosensor precisely detects glucose 4Jefferson scientists discover a key protein regulator of inflammation and cell death 2
...
Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....
...
... Zero Background Cloning Kit includes the pZErO-1 ... E. coli. The pZErO-1 vector utilizes positive ... size of the Zeocin resistance gene reduces ... and transformation efficiencies. The kit contains all ...
Biology Products: